Holen Sie sich die Stockscreener-App
8.28
1.60%
0.15
Schlusskurs vom Vortag:
$8.13
Offen:
$8.16
24-Stunden-Volumen:
145.61K
Relative Volume:
0.28
Marktkapitalisierung:
$432.88M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-6.4186
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
+5.09%
1M Leistung:
-3.84%
6M Leistung:
+4.82%
1J Leistung:
+43.15%
1-Tages-Spanne:
$8.11
$8.334
1-Wochen-Bereich:
$7.4801
$8.334
52-Wochen-Spanne:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.29 | 432.88M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.50 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.41 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.53 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.94 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.39 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Janney Montgomery Scott LLC Has $2.48 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy” - Defense World
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewswire
Breakthrough Treatment for Rare Brain Disease: Zevra's MIPLYFFA Earns Major Industry Recognition - StockTitan
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Zevra Takes Center Stage at Major Healthcare Investment Events - StockTitan
Cantor Fitzgerald Predicts ZVRA FY2025 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings - MarketBeat
Objective long/short (ZVRA) Report - Stock Traders Daily
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $21.57 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts - Defense World
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $7.25 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
Sanctuary Advisors LLC Trims Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Sanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00 - MarketBeat
13,551 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by XTX Topco Ltd - Defense World
(ZVRA) Investment Analysis and Advice - Stock Traders Daily
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - The Manila Times
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year - StockTitan
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Fmr LLC Acquires 2,312,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Restructures to Focus on Rare Diseases - MSN
A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - PharmaVoice
Zevra Therapeutics Announces Organizational Changes - The Manila Times
Zevra Therapeutics, Inc. Announces Departure of Executives - Marketscreener.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus Price Target from Brokerages - MarketBeat
Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat
Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan
Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):